Stelis Biopharma Raises Money
Posted on 03/19/2021
The biopharmaceutical division of Strides Pharma Science Limited, Stelis Biopharma, raised US$ 70 million in its Series B round and US$ 125 million in its Series C round. Stelis Biopharma raised money from investors such as TPG Growth, Route One, Think Investments, GMS Holdings, and a family office (Mankekar family).